Li Y - Search Results

1

Targeted immunotherapy for HER2-low breast cancer with 17p loss.

Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, He B, Miller KD, Radovich M, Schneider BP, Pahl A, Zhang X, Lu X. Li Y, et al. Sci Transl Med. 2021 Feb 10;13(580):eabc6894. doi: 10.1126/scitranslmed.abc6894. Sci Transl Med. 2021. PMID: 33568521 Free PMC article.

2

Regulators in the DNA damage response.

Liu Y, Li Y, Lu X. Liu Y, et al. Among authors: li y. Arch Biochem Biophys. 2016 Mar 15;594:18-25. doi: 10.1016/j.abb.2016.02.018. Epub 2016 Feb 13. Arch Biochem Biophys. 2016. PMID: 26882840 Review.

3

Amplification of USP13 drives ovarian cancer metabolism.

Han C, Yang L, Choi HH, Baddour J, Achreja A, Liu Y, Li Y, Li J, Wan G, Huang C, Ji G, Zhang X, Nagrath D, Lu X. Han C, et al. Among authors: li y, li j. Nat Commun. 2016 Nov 28;7:13525. doi: 10.1038/ncomms13525. Nat Commun. 2016. PMID: 27892457 Free PMC article.

4

MicroRNAs in DNA Damage Response, Carcinogenesis, and Chemoresistance.

Fang Y, Zhang L, Li Z, Li Y, Huang C, Lu X. Fang Y, et al. Among authors: li y, li z. Int Rev Cell Mol Biol. 2017;333:1-49. doi: 10.1016/bs.ircmb.2017.03.001. Epub 2017 Mar 31. Int Rev Cell Mol Biol. 2017. PMID: 28729023 Review.

5

Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.

Liu Y, Xu H, Van der Jeught K, Li Y, Liu S, Zhang L, Fang Y, Zhang X, Radovich M, Schneider BP, He X, Huang C, Zhang C, Wan J, Ji G, Lu X. Liu Y, et al. Among authors: li y. J Clin Invest. 2018 Jul 2;128(7):2951-2965. doi: 10.1172/JCI98727. Epub 2018 Jun 4. J Clin Invest. 2018. PMID: 29649003 Free PMC article.

6

Drug resistance and new therapies in colorectal cancer.

Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Van der Jeught K, et al. World J Gastroenterol. 2018 Sep 14;24(34):3834-3848. doi: 10.3748/wjg.v24.i34.3834. World J Gastroenterol. 2018. PMID: 30228778 Free PMC article. Review.

7

Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.

Li Y, Liu Y, Xu H, Jiang G, Van der Jeught K, Fang Y, Zhou Z, Zhang L, Frieden M, Wang L, Luo Z, Radovich M, Schneider BP, Deng Y, Liu Y, Huang K, He B, Wang J, He X, Zhang X, Ji G, Lu X. Li Y, et al. Nat Commun. 2018 Oct 22;9(1):4394. doi: 10.1038/s41467-018-06811-z. Nat Commun. 2018. PMID: 30349055 Free PMC article.

8

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Liu Y, Xu J, Choi HH, Han C, Fang Y, Li Y, Van der Jeught K, Xu H, Zhang L, Frieden M, Wang L, Eyvani H, Sun Y, Zhao G, Zhang Y, Liu S, Wan J, Huang C, Ji G, Lu X, He X, Zhang X. Liu Y, et al. Among authors: li y. Nat Commun. 2018 Nov 9;9(1):4718. doi: 10.1038/s41467-018-07264-0. Nat Commun. 2018. PMID: 30413718 Free PMC article.

9

Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.

Xu J, Liu Y, Li Y, Wang H, Stewart S, Van der Jeught K, Agarwal P, Zhang Y, Liu S, Zhao G, Wan J, Lu X, He X. Xu J, et al. Among authors: li y. Nat Nanotechnol. 2019 Apr;14(4):388-397. doi: 10.1038/s41565-019-0381-6. Epub 2019 Feb 25. Nat Nanotechnol. 2019. PMID: 30804480 Free PMC article.

10

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.

Xu J, Liu Y, Li Y, Wang H, Stewart S, Van der Jeught K, Agarwal P, Zhang Y, Liu S, Zhao G, Wan J, Lu X, He X. Xu J, et al. Among authors: li y. Nat Nanotechnol. 2019 May;14(5):496. doi: 10.1038/s41565-019-0417-y. Nat Nanotechnol. 2019. PMID: 30837690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

217,407 results

Search Page